PMID- 37378924
OWN - NLM
STAT- MEDLINE
DCOM- 20230630
LR  - 20230920
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Print)
IS  - 1513-7368 (Linking)
VI  - 24
IP  - 6
DP  - 2023 Jun 1
TI  - Clinical Management of Potential Toxicity of Abemaciclib and Approaches to Ensure 
      Treatment Continuation.
PG  - 1955-1962
LID - 90662 [pii]
LID - 10.31557/APJCP.2023.24.6.1955 [doi]
AB  - INTRODUCTION: The association between abemaciclib dose reduction and treatment 
      adherence is not clear. In this study, we examined real-world data of Japanese 
      patients with advanced breast cancer (ABC) to determine how abemaciclib dose 
      reduction is related to treatment continuation. METHODS: This retrospective 
      observational study involved 120 consecutive patients with ABC who received 
      abemaciclib from December 2018 to March 2021. The time to treatment failure (TTF) 
      was estimated using the Kaplan-Meier method. Univariate and multivariate analyses 
      were performed to identify factors associated with a TTF of >365 days (TTF365). 
      RESULTS: According to the dose reduction during treatment, the patients were 
      classified into 100, 200, and 300 mg/day abemaciclib groups. The 300 mg/day group 
      had a TTF of 7.4 months, whereas the 100 and 200 mg/day groups had significantly 
      longer TTFs (17.9 and 17.3 months, respectively; P = 0.0002). In this study, 
      relative to the 300 mg/day arm, TTF was improved in 200mg/day arm and 100 mg/day 
      arm (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.33-0.93) and [HR], 
      0.37; 95% CI, 0.19-0.74). For patients who received 300mg/day of abemaciclib dose 
      arm, 200mg/day, and 100mg/day, the median TTF was 7.4 ,17.9 and 17.3 months. The 
      frequently reported adverse effects (AEs) were anemia, increased blood creatinine 
      levels, diarrhea, and neutropenia (90%, 83%, 83%, and 75% of the patients, 
      respectively). Neutropenia, fatigue, and diarrhea were the top AEs causing dose 
      reduction. A multivariate analysis that examined factors associated with 
      achieving TTF 365 confirmed that dose down was an important factor (odds ratio: 
      3.95, 95% confidence interval: 1.68-9.36, P = 0.002). CONCLUSIONS: In this study, 
      the 100 and 200 mg/day groups had a longer TTF than the 300 mg/day group, and 
      dose reduction was identified as an important factor in achieving longer TTF.
FAU - Takada, Shinya
AU  - Takada S
AUID- ORCID: 0000-0002-6845-5533
AD  - Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center, 
      Sapporo, Japan.
FAU - Maeda, Hideki
AU  - Maeda H
AD  - Department of Breast Surgery, National Hospital Organization Hokkaido Cancer 
      Center, Sapporo, Japan.
FAU - Umehara, Kengo
AU  - Umehara K
AD  - Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center, 
      Sapporo, Japan.
FAU - Kuwahara, Sayuri
AU  - Kuwahara S
AD  - Department of Breast Surgery, National Hospital Organization Hokkaido Cancer 
      Center, Sapporo, Japan.
FAU - Yamamoto, Mitsugu
AU  - Yamamoto M
AD  - Department of Breast Surgery, National Hospital Organization Hokkaido Cancer 
      Center, Sapporo, Japan.
FAU - Tomioka, Nobumoto
AU  - Tomioka N
AD  - Department of Breast Surgery, National Hospital Organization Hokkaido Cancer 
      Center, Sapporo, Japan.
FAU - Takahashi, Masato
AU  - Takahashi M
AD  - Department of Breast Surgery, Hokkaido University Hospital, Sapporo, Japan.
FAU - Watanabe, Kenichi
AU  - Watanabe K
AD  - Department of Breast Surgery, National Hospital Organization Hokkaido Cancer 
      Center, Sapporo, Japan.
FAU - Hashishita, Hirokazu
AU  - Hashishita H
AD  - Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center, 
      Sapporo, Japan.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20230601
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 60UAB198HK (abemaciclib)
RN  - 0 (Aminopyridines)
RN  - 0 (Benzimidazoles)
SB  - IM
MH  - Humans
MH  - Female
MH  - Treatment Outcome
MH  - Aminopyridines/adverse effects
MH  - Benzimidazoles/adverse effects
MH  - *Neutropenia/chemically induced
MH  - *Breast Neoplasms/etiology
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
PMC - PMC10505863
OTO - NOTNLM
OT  - Metastatic breast cancer
OT  - abemaciclib
OT  - appropriate supportive care
OT  - dose reduction
COIS- The authors declare no conflicts of interest.
EDAT- 2023/06/28 13:08
MHDA- 2023/06/30 06:42
PMCR- 2023/03/01
CRDT- 2023/06/28 11:17
PHST- 2023/01/13 00:00 [received]
PHST- 2023/06/30 06:42 [medline]
PHST- 2023/06/28 13:08 [pubmed]
PHST- 2023/06/28 11:17 [entrez]
PHST- 2023/03/01 00:00 [pmc-release]
AID - 90662 [pii]
AID - 10.31557/APJCP.2023.24.6.1955 [doi]
PST - epublish
SO  - Asian Pac J Cancer Prev. 2023 Jun 1;24(6):1955-1962. doi: 
      10.31557/APJCP.2023.24.6.1955.